Galectin Therapeutics (NASDAQ:GALT) Insider Sells $99,446.10 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 25,499 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $3.90, for a total transaction of $99,446.10. Following the transaction, the insider directly owned 21,446 shares in the company, valued at $83,639.40. The trade was a 54.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Khurram Jamil also recently made the following trade(s):

• On Tuesday, January 6th, Khurram Jamil sold 21,446 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.65, for a total transaction of $78,277.90.
• On Friday, January 2nd, Khurram Jamil sold 13,055 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total value of $54,831.00.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The stock was sold at an average price of $7.04, for a total value of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total value of $662,509.99.

Galectin Therapeutics Trading Down 9.6%

Galectin Therapeutics stock opened at $3.20 on Friday. The stock has a fifty day moving average price of $5.24 and a 200 day moving average price of $4.38. Galectin Therapeutics Inc. has a 52 week low of $1.07 and a 52 week high of $7.13. The firm has a market capitalization of $206.30 million, a P/E ratio of -5.42 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities analysts predict that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Galectin Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nuveen LLC purchased a new stake in shares of Galectin Therapeutics in the first quarter worth about $34,000. Atwood & Palmer Inc. acquired a new position in shares of Galectin Therapeutics during the third quarter worth $42,000. Archer Investment Corp purchased a new position in shares of Galectin Therapeutics in the third quarter valued at $47,000. Bank of America Corp DE grew its holdings in Galectin Therapeutics by 101.4% during the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after purchasing an additional 19,316 shares in the last quarter. Finally, Hudson Bay Capital Management LP purchased a new stake in Galectin Therapeutics during the 3rd quarter worth $63,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright upped their price target on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.